PT  - JOURNAL ARTICLE
AU  - Castellone, Donna D
TI  - Past, Present and Future Options in the Treatment of Hemophilia A
AID  - 10.29074/ascls.118.001032
DP  - 2019 Jan 01
TA  - American Society for Clinical Laboratory Science
PG  - ascls.118.001032
4099  - http://hwmaint.clsjournal.ascls.org/content/early/2019/10/26/ascls.118.001032.short
4100  - http://hwmaint.clsjournal.ascls.org/content/early/2019/10/26/ascls.118.001032.full
AB  - Patients who present with hemophilia A require treatment to replace low levels of Factor VIII (FVIII). Intervention can either be on demand or prophylactically. The goal of therapy is to prevent joint bleeds that lead to permanent damage. The progression of therapy in hemophilia A has provided patients with options resulting in a greatly improved quality of life. The newest development of gene therapy, to replace FVIII, may be the answer to cure this disease. This review provides a historical account of the treatment for hemophilia A as well as current available treatment options.